Douglas R. Moore, MD
Douglas R. Moore, MD

Douglas R. Moore, MD

Assistant Professor
School of Medicine

Academic Appointments

Department

  • Medicine

Position

  • Assistant Professor

Publications and Presentations

Publications


  • Dull, S.K., Jagan, N., Moore, D.R., DePew, Z.S., Morrow, L.E., Malesker, M.
    Diffuse Alveolar Hemorrhage Following Pirfenidone Initiation. Journal of Pharmacy Practice. 2019.
    https://doi.org/10.1177/0897190019841731. PMID: 30987503, J Pharm Pract, April 15 2019, 2019
  • Gornatla, R., Jagan, N., Moore, D.R., Berim, I., Maki, S.
    Organizing Pneumonia and Massive Hemoptysis: Rare but Potentially Fatal. Critical Care Medicine. 47(1):567, January 2019, Critical Care Medicine, 47(1);567, 2019
  • Nonspecific Interstitial Pneumonitis
    Ali S. Nayfeh; Douglas R. Moore.
     , StatPearls, 2018
  • Gapp, J., Krishnan, M., Ratnaraj, F., Schroell, R.P., Moore, D.
    Cardiac Arrhythmias Resulting from a Peripherally Inserted Central Catheter: Two Cases and a Review of the Literature.
     , The Cureus Journal of Medical Science, 9 (6):, e130, 2017
  • Moore, D.R., Morrow, L.E., Malesker, M.A. Prolonged Extrication as a Risk Factor for Pneumonia in Trauma Patients Involved in a Motor Vehicle Accident., Chest, 144, 379A, 2013
  • Morrow, L.E., Deutz, C., Desai, K., Holweger, J., Moore, D.R., Malesker, M.A. Changes in the CPIS are Associated with Clinical Outcomes in Healthcare Associated Pneumonia., Chest, 140, 899A, 2011
  • Morrow, L.E., Moore, D.R., Malesker, M.A. Homelessness as a Risk Factor for Infection With Drug-Resistant Pathogens.
     , American Journal of Respiratory and Critical Care Medicine, 183, A3927, 2011

Presentations

  • International ATS Conference: A Challenging Case of Disseminated Sarcoidosis; Dallas, TX; May 2019; pending presentation by Dr. Noor Addasi
     , 2019
  • Creighton University Pulmonary Grand Rounds. Literature Review and Updates in Cooling after Cardiac Arrest: Should Everyone just chill?
     , 2019

  • Society of Critical Care Medicine 2019 Critical Care Congress: Code Sepsis: We’re on the Clock; San Diego, CA; February 2019; presentation by Dr. Michael Klug
     , 2019

  • Society of Critical Care Medicine 2019 Critical Care Congress: Organizing Pneumonia and Massive Hemoptysis: Rare but Potentially Fatal; San Diego, CA; February 2019; presentation by Dr. Ram Gorantla
     , 2019
  • Creighton University Pulmonary Grand Rounds. Steroids in the ICU
    Omaha, Nebraska. February 9th, 2018, 2018
  • 13th Annual Pulmonary, Critical Care and Sleep Medicine Conference - Steriods in the ICU; Fact amd Fiction, 2017
  • 11th Annual Pulmonary, Critical Care and Sleep Medicine Conference - The Top 5 Publications in Critical Care, 2015
  • 12th Annual Pulmonary, Critical Care and Sleep Medicine Conference - Managing the Rural Patient with Pulmonary Disease, 2015
  • Creighton University Pulmonary Grand Rounds. Lung Cancer Screening - What’s the Evidence and Where Do We Go From Here?, 2014
  • International ACCP Conference: Prolonged Extrication as a Risk Factor for Pneumonia in Trauma Patients Involved in a Motor Vehicle Accident; Chicago, IL, 2013
  • National ACP Conference: Rare Malignancy With Metastasis 16 Years Following Primary Resection; San Francisco, CA, 2013
  • Creighton University Pulmonary Grand Rounds. Operability in Lung Cancer, 2013
  • International ACCP Conference: Changes in the CPIS are Associated with Clinical Outcomes in Healthcare Associated Pneumonia; Honolulu, HI, 2011
  • International ATS Conference: Homelessness as a Risk Factor for Infection With Drug-Resistant Pathogens; Denver, CO, 2011
  • Creighton University Internal Medicine Grand Rounds. Management of Shock, 2011

Research and Scholarship

Grant Funding Received

  • Role: Sub-investigator Source: Boehringer Ingelheim-1199.247 Type: Industry-sponsored, multicenter trial Title: A Double-Blind, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Nintedanib over 52 weeks in Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Dates: 4/2017-present
  • Role: Sub-investigator Source: Boehringer Ingelheim-1199.0248 Type: Industry-sponsored, multicenter trial Title: An Open-Label Extension Trial of the Long-term Safety of Nintedanib in Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Dates: Presently in start-up
  • Role: Sub-investigator Source: Galapagos GLPG1690-CL-303 Type: Industry-sponsored, multicenter trial Title: A Phase 3, Randomized, Double-blind, Parallel-Group, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Two Doses of GLPG1690 in Addition to Local Standard of Care for Minimum 52 weeks in Subjects with Idiopathic Pulmonary Fibrosis Dates: Presently in start-up

Awards and Honors

  • Multiple “AlegentOne” Awards, 2013
  • Multiple “Target 100” Awards, 2009
  • Nominee, Alpha Omega Alpha, 2007